- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.11. | OS Therapies reports Q3 results | 2 | Seeking Alpha | ||
| 15.11. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 15.11. | OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update | 202 | Business Wire | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported... ► Artikel lesen | |
| 15.11. | OS Therapies Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11. | OS Therapies Inc - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | - | SEC Filings | ||
| OS THERAPIES Aktie jetzt für 0€ handeln | |||||
| 12.11. | OS Therapies files to sell $15M in common stock for holders | 1 | Seeking Alpha | ||
| 12.11. | OS Therapies Inc - S-1, General form for registration of securities | - | SEC Filings | ||
| 28.10. | OS Therapies Inc - 8-K, Current Report | - | SEC Filings | ||
| 28.10. | OS Therapies expands board with biopharma veterans | 3 | Investing.com | ||
| 13.09. | OS Therapies announces development of novel cancer therapies | 1 | Investing.com | ||
| 11.09. | OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate Platform Using Proprietary Silicone Linker Platform in Preclinical Models | 253 | ACCESSWIRE | Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancerStrong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancerStrong... ► Artikel lesen | |
| 03.09. | EF Hutton sets Buy rating for OS Therapies stock on cancer approach | 1 | Investing.com | ||
| 29.08. | OS Therapies Completes OST-HER2 Osteosarcoma Trial Dosing | 1 | Investing.com | ||
| 27.08. | The Investing Authority to Host Breakout Session with OS Therapies LIVE on X | 246 | ACCESSWIRE | NEW YORK, NY / ACCESSWIRE / August 27, 2024 / The Investing Authority is thrilled to announce that they will be hosting a breakout session with OS Therapies live on X. The event will feature discussions... ► Artikel lesen | |
| 22.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Brookline Capital sets $9 target on OS Therapies, bullish on cancer tech | 1 | Investing.com | ||
| 22.08. | OS Therapies Clarifies CUSIP of Common Stock | 466 | ACCESSWIRE | New York, NY, August 22, 2024 OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today provided a clarification... ► Artikel lesen | |
| 16.08. | OS Therapies reports Q2 results | 1 | Seeking Alpha | ||
| 15.08. | OS Therapies Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08. | OS Therapies Reports Second Quarter 2024 Financial Results | 326 | ACCESSWIRE | Successful IPO that raised $6.4 million on July 31, 2024, without issuing any warrants, occurred after the end of the second quarter and is not reflected in reported financialsConversion of all reported... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,475 | -0,48 % | QIAGEN N.V.: QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR-Assays und NGS-Panels für die mikrobielle Analyse ein | QIAGEN führt das erste Design-Tool für individuell anpassbare digitale PCR-Assays im Markt ein, ausgestattet mit fortschrittlichen Design-Algorithmen für verschiedene mikrobielle Anwendungen und kundenspezifische... ► Artikel lesen | |
| EVOTEC | 8,585 | -3,86 % | Evotec Aktie: Alarm! Probleme bahnen sich an | ||
| JANUX THERAPEUTICS | 62,40 | +55,46 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| BIONTECH | 111,70 | +0,09 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,500 | -0,99 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| CITIUS ONCOLOGY | 1,750 | +71,57 % | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,870 | +0,91 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| VERVE THERAPEUTICS | 7,430 | +4,13 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| GUBRA | 89,80 | -7,99 % | AKTIONÄR-Depotwert Gubra: Nächstes Kaufsignal - neue Rekorde in Sicht | Die Bullen bleiben beim AKTIONÄR-Depotwert Gubra am Drücker. Zum Start in die neue Handelswoche strebt die Aktie des dänischen Wirkstoffforschers an der Heimatbörse in Kopenhagen auf ein neues Verlaufshoch... ► Artikel lesen | |
| SENTI BIOSCIENCES | 6,870 | -32,05 % | Senti Biosciences, Inc.: Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory ... | - 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile - - Dose escalation is continuing with additional... ► Artikel lesen | |
| BB BIOTECH | 40,350 | -0,12 % | BB Biotech Aktie: Klare Gewinne sichtbar! | ||
| COHERUS | 1,925 | +48,02 % | Coherus shares surge on $558M Udenyca divestiture deal | ||
| CABALETTA BIO | 3,730 | -9,36 % | Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update | - Nine patients enrolled as of August 5, 2024 across the RESET clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling - - Additional clinical data... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,880 | -3,25 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
| AMGEN | 265,40 | +0,21 % | Opening Bell: Bitcoin, Amgen, Eli Lilly, The GEO Group, Amazon, Ebay, Walmart, Archer Aviation | Der Start in die neue Woche kann sich für die Wall Street sehen lassen. Der Dow Jones und der S&P 500 erreichten gestern neue Bestmarken. Heute deutet sich bei den großen Indizes ein verhaltener Start... ► Artikel lesen |
Das Unternehmen OS THERAPIES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,910 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.
